Top Page
Cutia Therapeutics
(2487)
Cutia Therapeutics (2487) vs. iShares MSCI Hong Kong ETF (EWH)
Cutia Therapeutics Business Overview & Revenue Model
Cutia Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 250.33M | 279.62M | 137.62M | 11.37M | 2.04M |
| Gross Profit | 125.19M | 143.46M | 71.01M | 7.94M | 1.61M |
| EBITDA | -422.82M | -430.69M | -1.92B | -535.19M | -309.23M |
| Net Income | -472.27M | -433.81M | -1.96B | -555.84M | -319.58M |
Balance Sheet | |||||
| Total Assets | 1.12B | 1.39B | 1.71B | 1.45B | 1.49B |
| Cash, Cash Equivalents and Short-Term Investments | 681.51M | 876.15M | 1.27B | 1.08B | 1.38B |
| Total Debt | 290.40M | 320.94M | 243.75M | 54.13M | 26.53M |
| Total Liabilities | 359.62M | 418.51M | 357.76M | 2.69B | 2.29B |
| Stockholders Equity | 756.62M | 974.73M | 1.35B | -1.25B | -790.51M |
Cash Flow | |||||
| Free Cash Flow | -209.64M | -468.66M | -437.23M | -371.50M | -185.76M |
| Operating Cash Flow | -196.82M | -442.98M | -381.31M | -236.19M | -159.88M |
| Investing Cash Flow | 272.88M | 316.07M | -203.58M | 462.06M | -410.65M |
| Financing Cash Flow | 32.50M | 37.84M | 588.32M | -10.25M | 480.76M |
Cutia Therapeutics Technical Analysis
Cutia Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$4.88B | 26.46 | 4.45% | ― | -8.11% | ― | |
45 Neutral | HK$2.15B | ― | -55.33% | ― | -100.00% | 30.68% | |
45 Neutral | HK$5.49B | -109.29 | -5.08% | ― | 770.20% | 87.27% | |
42 Neutral | HK$8.81B | -19.44 | -95.84% | ― | -55.64% | -158.67% | |
41 Neutral | HK$2.32B | ― | -48.42% | ― | 25.89% | 12.90% | |
39 Underperform | HK$2.78B | ― | -129.05% | ― | ― | -18.99% |
Cutia Therapeutics Corporate Events
Cutia Therapeutics has announced that their Abbreviated New Drug Application for CU-40105, a self-developed topical finasteride spray for treating androgenetic alopecia, has been accepted by China’s National Medical Products Administration. This development is expected to enhance the company’s product offerings in scalp disease treatments, potentially allowing for a differentiated commercialization strategy and broader market coverage. The acceptance marks a significant step in expanding their product matrix and targeting diverse consumer needs in the androgenetic alopecia market.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
Cutia Therapeutics announced that a post-hoc analysis of their Phase III clinical trial for CU-10201, a topical 4% minocycline foam, has been accepted for presentation at the 20th CDA Annual Meeting. The analysis revealed that CU-10201 demonstrates a rapid onset of action in treating moderate to severe facial acne vulgaris in Chinese patients, showing significant improvement in inflammatory lesions within the first two weeks of treatment. This suggests that CU-10201 could become a significant treatment option for acne vulgaris, enhancing the company’s position in the dermatological market.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
Cutia Therapeutics has successfully completed the placement of 28,904,000 new shares under a general mandate, raising approximately HK$240.27 million in net proceeds. The funds will be used to advance the company’s research and development pipeline, particularly in areas such as localized adipose accumulation management and skin diseases, as well as to deploy necessary production facilities and equipment.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
Cutia Therapeutics announced the placement of 28,904,000 new shares under a general mandate, representing approximately 9.05% of its issued shares. The shares are priced at HK$8.40 each, generating estimated net proceeds of HK$240.26 million. This strategic move is expected to enhance the company’s financial position and support its ongoing growth in the dermatology sector.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
Cutia Therapeutics, a company incorporated in the Cayman Islands, has announced changes in its board of directors. Mr. Tao Tak Yan Dennis has resigned from his position as an independent non-executive director and from his roles in the audit and nomination committees to focus on personal commitments. The company has appointed Mr. Zhang Zhisong as the new independent non-executive director, effective August 28, 2025. Mr. Zhang brings extensive financial experience from previous roles at TUHU Car Inc., Goldman Sachs, Citigroup, Merrill Lynch, and Deutsche Bank. His appointment is expected to strengthen the company’s governance and strategic direction.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
Cutia Therapeutics has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board has established three committees: the Audit Committee, Remuneration Committee, and Nomination Committee, each with designated members and chairpersons. This announcement reflects the company’s governance structure and may influence its strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
Cutia Therapeutics announced the establishment of a Nomination Committee as part of its corporate governance structure. This committee, formed by the board of directors, aims to ensure diversity and independence in its membership, which may enhance the company’s decision-making processes and strengthen its governance framework.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
Cutia Therapeutics has announced a change in its company secretary, authorized representative, and process agent, with Ms. Chan Sze Ting resigning and Mr. Leung Chi Kit taking over the roles effective August 28, 2025. Additionally, the company has relocated its principal place of business in Hong Kong to a new address, indicating strategic operational adjustments.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
Cutia Therapeutics has announced significant advancements in its product pipeline and business operations for the first half of 2025. The company received marketing approval for its CU-40102 topical finasteride spray for androgenetic alopecia and CU-10201 topical minocycline foam for acne vulgaris from the NMPA, with CU-40102 also approved by the Hong Kong Department of Health. These approvals mark a milestone for Cutia, highlighting its innovative approach in the dermatology sector and paving the way for commercialization activities, potentially enhancing its market position and offering new treatment options for patients.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.